Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.34 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.34 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687239 | 1.00 | AKR1B1 (0.41) | AKR1B1GAAPDE4DRORCSMN1; SMN2 | |
| SCHEMBL29223298 | 0.81 | RORC (0.38) | PDE4DRORCSMN1; SMN2LMNA | |
| SCHEMBL17682382 | 0.78 | AKR1B1 (0.44) | AKR1B1GAASMN1; SMN2PTGS2PTGDR2 | |
| SCHEMBL22870401 | 0.77 | AKR1B1 (0.43) | AKR1B1PDE4DLMNAPTGS2PTGDR2 | |
| SCHEMBL29607174 | 0.77 | AKR1B1 (0.43) | AKR1B1PDE4DLMNAPTGS2PTGDR2 | |
| SCHEMBL17681855 | 0.72 | RORC (0.39) | RORC | |
| SCHEMBL29686863 | 0.72 | RORC (0.39) | RORC | |
| SCHEMBL24495428 | 0.71 | ALDH1A1 (0.41) | AKR1B1PDE4DSMN1; SMN2PTGS2PTGDR2 | |
| SCHEMBL29686660 | 0.71 | ALDH1A1 (0.41) | AKR1B1PDE4DSMN1; SMN2PTGS2PTGDR2 | |
| SCHEMBL8668157 | 0.70 | AKR1B1 (0.52) | AKR1B1GAAPDE4DSMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507332-A | Octahydroisoquinolinyl derivatives | UCB生物制药有限责任公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022117678-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-09 | — | — | WO | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313677-A1 | Isoindoline Derivatives | OPRD1, ADRA1D, DRD2 | AKR1B1 975/4885GAA 4089/4885PDE4D 213/4885 |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | AKR1B1 1371/4885GAA 3535/4885PDE4D 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.